ClinicalTrials.gg
RecruitingNCT07308548NASH/MASHUpdated Dec 29, 2025

A Trial to Evaluate the Efficacy, Safety, PK, and PD of HP515 in Non - Alcoholic Fatty Liver Disease ( NASH/MASH )

A Phase 2 interventional study of HP515 10 mg Tablet and Placebo of HP515 10 mg Tablet in NAFLD (Non-alcoholic Fatty Liver Disease), sponsored by Hinova Pharmaceuticals Inc.. Recruiting at 2 sites in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-12-29.

Sponsored by Hinova Pharmaceuticals Inc. · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Aug 2026, 3 months ago, but the record still lists the study as recruiting.
  • Started Oct 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 143 studies in Non-alcoholic Fatty Liver Disease with a site in China — 42 open to participants now, 53 under way, 5 of them phase 3. Non-alcoholic Fatty Liver Disease · China.

Planned enrollment
62nd of 89
80 · median 112
Started
2025
with 10 others
Phase 2
20 of 143
3 open now
Primary completion
2026-08
later than 25 of 52 live
Registered
132nd of 143
by date

Among the 143 studies in Non-alcoholic Fatty Liver Disease with a site in China, this one is the 62nd largest by planned enrollment of the 89 interventional ones that give a count, is one of 11 that started in 2025, is one of 20 in phase 2, reaches primary completion later than 25 of the 52 other live ones, and was the 132nd registered.

Non-alcoholic Fatty Liver Disease

1,618 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.

Browse Non-alcoholic Fatty Liver Disease studies →

Open to participants now

42 of the 143 studies in Non-alcoholic Fatty Liver Disease with a site in China are open now. Recruiting first, the newest first:

36 more — sign in →

All 42 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 143 studies in Non-alcoholic Fatty Liver Disease with a site in China, or all of them as a file.
02

Study summary

Primary Objective:

  • To evaluate the efficacy of HP515 tablets in participants with non-alcoholic fatty liver disease.

Secondary objectives:

  • To evaluate the safety of HP515 tablets in participants with non-alcoholic fatty liver disease;
  • To evaluate the pharmacokinetic of HP515 tablets in participants with non-alcoholic fatty liver disease;
  • To evaluate the pharmacodynamic effects of HP515 tablets in participants with non-alcoholic fatty liver disease;

Exploratory objective:

  • To evaluate the impact of HP515 tablets on target markers in participants with non-alcoholic fatty liver disease.

The study includes a screening period of 4 weeks, a treatment period of 12 weeks, and a safety follow-up period of 4 weeks.

Read the detailed description

This study is a multicenter, randomized, double-blind, placebo-controlled Phase IIa clinical trial conducted in participants with non-alcoholic fatty liver disease.

The trial includes a screening period (D-28 to D-1), a treatment period (Week 1 to Week 12), and a safety follow-up period (Week 13 to Week 16).

Eligible participants are randomized based on stratification factors \[D1 body weight \<80 kg vs ≥80 kg]. Participants with body weight \<80 kg are randomized in a 2:2:1 ratio to HP515 40 mg group, HP515 50 mg group, and placebo group. Participants with body weight ≥80 kg are randomized in a 2:1 ratio to HP515 60 mg group and placebo group. Each HP515 group enrolls 20 participants, totaling 60 participants, and the placebo group enrolls 20 participants, with a total of 80 participants enrolled.

All participants receive 12 weeks of medication, and the entire study process includes evaluation of efficacy and safety for all participants, as well as evaluation of targeted biomarkers.

All participants provided Pop-PK blood samples on an empty stomach before morning dosing at the end of Weeks 2, 6, 8, 10, and 12. Intensive blood sampling was performed for all participants completing 4 weeks of treatment or withdrawing early before the end of Week 4. Participants who completed the early withdrawal visit after at least 1 week of continuous dosing and did not discontinue medication prior to the in-person visit were encouraged to complete intensive PK sampling. ≥MRI-PDFF and FibroScan examinations were performed during the screening period, at 12 weeks of treatment, and at early withdrawal visits (requiring a minimum of 6 weeks of medication duration). Participants who completed 12 weeks of treatment completed the treatment phase, while those who completed the 16-week safety follow-up completed the trial.

03

Conditions studied

  • NAFLD (Non-alcoholic Fatty Liver Disease)

Keywords

  • non-alcoholic
  • Fatty Liver
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants must voluntarily sign the form before the trial and fully understand the trial content, process, and possible adverse reactions.
  2. Participants must be aged between 18 and 65 years old, including those at the borderline age.
  3. At the screening stage, the liver fat fraction must be ≥ 10%
  4. Female participants must not donate eggs from the start of the screening until the end of the study and within 28 days after discontinuing the study drug; male participants must not donate sperm from the start of the screening until the end of the study and within 28 days after discontinuing the study drug.
  5. Participants must agree to use during the study period and for the next 6 months after the last administration of the study drug, and must agree to continuously use effective contraceptive measures.

Exclusion criteria

Exclusion Criteria:

  1. The participants have known or suspected allergic reactions
  2. Liver indicates cirrhosis or the participant has been clinically diagnosed with cirrhosis
  3. Type 1 diabetic patients or those with poorly controlled type 2 diabetes ( ≥ 8.0%);
  4. Suspected other liver and gallbladder diseases through medical history and laboratory tests, which, based on the investigator's judgment, may affect safety or efficacy evaluation
  5. Any abnormality in thyroid function tests with clinical significance or a previous history of thyroid disease
  6. Within the previous 1 year, had myocardial infarction, unstable angina pectoris, coronary artery bypass surgery, cerebral infarction, cerebral hemorrhage, subarachnoid hemorrhage or , or other cardiovascular and cerebrovascular events that led to hospitalization;
  7. History of liver transplantation or planning to undergo liver transplantation;
  8. Had significant changes in diet or exercise habits in the past 2 months or a weight change of more than 5%;
  9. Participants who used drugs that changed the activity of CYP2C8 of liver enzymes within 4 weeks or 5 half-lives (whichever is longer), including strong inhibitors and inducers of liver metabolic enzymes;
  10. Pregnant or lactating women;
  11. Participants with to MRI scans;
  12. Participants judged by the investigator to be unsuitable for participation in the study.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    HP515 40mg group

    Two HP515 20 mg Tablets +Two Placebos of HP515 10mg Tablets

    Drug: Placebo of HP515 10 mg Tablet · Drug: HP515 20 mg Tablet

  • Experimental
    HP515 50mg group

    Two HP515 20mg Tablets + One HP515 10mg Tablet + One Placebo of HP515 10mg Tablet

    Drug: HP515 10 mg Tablet · Drug: Placebo of HP515 10 mg Tablet · Drug: HP515 20 mg Tablet

  • Experimental
    HP515 60mg group

    Two HP515 20mg Tablets + Two HP515 10mg Tablets

    Drug: Placebo of HP515 10 mg Tablet · Drug: HP515 20 mg Tablet

  • Placebo comparator
    Placebo

    Two Placebos of HP515 20mg Tablet +Two Placebos of HP515 10mg Tablet

    Drug: Placebo of HP515 10 mg Tablet · Drug: Placebo of HP515 20mg Tablet

Interventions

  • DrugHP515 10 mg Tablet

    Provided by provided by Hinova Pharmaceuticals Inc .Storage: Protect from light, keep sealed, store at ≤25°C. HP515 10mg Tablet, qd

  • DrugPlacebo of HP515 10 mg Tablet

    Provided by provided by Hinova Pharmaceuticals Inc .Storage: Protect from light, keep sealed, store at ≤25°C. Placebo of HP515 10 mg Tablet ,qd , 12 weeks.

  • DrugHP515 20 mg Tablet

    Provided by provided by Hinova Pharmaceuticals Inc .Storage: Protect from light, keep sealed, store at ≤25°C; HP515 20 mg Tablet, qd,12 weeks

  • DrugPlacebo of HP515 20mg Tablet

    Provided by provided by Hinova Pharmaceuticals Inc .Storage: Protect from light, keep sealed, store at ≤25°C; Placebo of HP515 20 mg Tablet, qd,12 weeks

06

What researchers measure

Primary outcomes

  1. The relative change in liver fat fraction from the baseline by magnetic resonance proton density fat fraction (MRI-PDFF).

    Relative change from baseline is calculated for each subject as 100% x \[(Week 12 Value - Baseline Value)/Baseline Value\].

    Time frame: Baseline and Week 12.

Secondary outcomes

  1. The absolute change in liver fat fraction from the baseline by magnetic resonance proton density fat fraction (MRI-PDFF).

    Absolute change from baseline is calculated for each subject as \[(Week 12 Value - Baseline Value)\].

    Time frame: Baseline and Week 12.

  2. At the 12-week treatment period, through MRI-PDFF measurement, the proportion of participants whose liver fat fraction decreased by more than 30% or 50%.

    Proportion of subjects with ≥30% or 50% relative reduction in liver fat content by MRI-PDFF at Week 12

    Time frame: Week 12.

  3. The percentage changes of blood lipid

    Percent change from baseline of low-density lipoprotein cholesterol (LDL-C)

    Time frame: Baseline, up to 12 weeks.

  4. Number and Percentage of participants with any Treatment Emergent adverse events as assessed by CTCAE v5.0.[Time Frame: up to 16 weeks.]

    Safety of HP515 based on Adverse Events and Changes in Laboratory Values、vital signs, physical examination, 12-lead electrocardiogram.

    Time frame: Up to 16 weeks.

  5. Assessment of pharmacokinetic parameters of HP515 : Maximum concentration (Cmax)

    Time frame: Baseline, up to 12 weeks

  6. Assessment of pharmacokinetic parameters of HP515 : area under the concentration-time curve (AUC)

    Time frame: Base line and up to 12 weeks

  7. Assessment of pharmacokinetic parameters of HP515: Time to maximum concentration (Tmax)

    Time frame: Base line and up to 12 weeks

07

Study locations

1 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — All the unpublished information provided by the sponsor to the researchers and any data generated from this trial are confidential and are exclusive to the sponsor. The researchers agree to keep this information confidential and use it only to complete this study. Such information may not be used for any other purpose without the written consent of the sponsor. The trial results will be presented in the form of a clinical trial report (CSR), which includes the data from all participating units. Any data derived from the trial and involving copyright protection belong to the sponsor. The sponsor has the right to publish these materials and information.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Aug 2026, 10 months after the start.

Of 132 industry-sponsored phase 2 interventional studies under Non-alcoholic Fatty Liver Disease, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 30. This study's planned 10 months is below that.

Counting every sponsor, half of 185 studies reached it within 26 months; a quarter within 16 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 14, 2025
First posted
Dec 29, 2025
StartActual
Oct 11, 2025
Primary completionEst.
Aug 13, 2026
CompletionEst.
Dec 31, 2026
Last update
Dec 29, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07308548
Lead sponsor
Hinova Pharmaceuticals Inc.
Responsible party
Sponsor
First posted
Dec 29, 2025
Start date
Oct 11, 2025
Primary completion
Aug 13, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Dec 29, 2025

Study contacts

Yang Ming YM Chief physician
Contact
ymicecream@163.com
+86-15810092973
Wei WL chief physician
Contact
weelai@163.com
+86-15810092973

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion